Best Biopharma Outsourcing Companies in Cambridge, United States
The 36 best Biopharma Outsourcing companies in Cambridge, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Hydra Biosciences.
Our analysis of 50 Biopharma Outsourcing companies
$6.3b in tracked funding; 77% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Biopharma Outsourcing companies in Cambridge
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Hydra Biosciences Develops ion-channel based drugs for diabetic neuropathy, allergic asthma and pulmonary diseases | $112M | 138 mo ago | Series E | — | 2001 | — | 397 patents Small‑molecule TRPC ion channel modulators (TRPC6/5) for therapeutic applications | — |
| 2 | Matchpoint Therapeutics Provider of small molecular medicine development and analytics services | $100M | 47 mo ago | Series A | Tinghu Zhang Co-Founder | 2021 | — | — | — |
| 3 | DoubleRainbow Biosciences Developer of sustainable therapeutics and nutraceuticals using natural product manufacturing | $15M | 70 mo ago | Series B | Tian Xu Co-Founder | 2017 | — | — | — |
| 4 | Lytica Therapeutics Developer of therapeutic drugs | $12M | 18 mo ago | Series A | Jim LaTorre CEO | 2019 | — | — | — |
| 5 | Kano Therapeutics Developer of circular single-stranded DNA for targeted gene-length DNA correction | $7M | 28 mo ago | Seed | Mark Bathe Co-Founder | 2021 | WordPressMySQLPHP+15 | — | — |
| 6 | Leadart Biotechnologies Provider of drug target discovery platform and probe library | $6M | 44 mo ago | Seed | Yufeng Zhao Co-Founder | 2017 | — | — | — |
| 7 | Eulysis Provider of diabetes management and lifestyle modification services | $5M | 135 mo ago | Series A | — | 2010 | — | — | — |
| 8 | MedPanel Global healthcare market research partner providing insights for biopharma and medtech | $2M | 140 mo ago | Acquired | Janet Bernard CEO & President | 1999 | — | — | — |
| 9 | Cytel Provider of data analysis and statistical solutions for the life sciences industry | $2M | 106 mo ago | Acquired | Cyrus Mehta Co-Founder & President | 1987 | WordPressApple iCloud MailMicrosoft 365+31 | 43 patents AI-driven clinical trial design software integrating systematic literature review and knowledge-based recommendations | — |
| 10 | IOTA Pharma Offering fragment-based drug discovery products and services | $906K | 116 mo ago | Deadpooled | — | 2007 | — | — | — |
| 11 | Pearl Bio Developer of biomaterial platform using synthetic biology for diverse chemistry applications | $844K | 27 mo ago | Funding Raised | Amy Cayne Schwartz Co-Founder | 2021 | — | — | — |
| 12 | Snapdragon Chemistry CDMO providing API development, manufacturing, and analytical services | $225K | 72 mo ago | Acquired | Tim Jamison Co-Founder | 2014 | — | 9 patents Automated online chromatographic sample dilution/preparation and continuous‑flow photoreactor systems. | — |
| 13 | Prometrika Full-service CRO providing innovative clinical development solutions for biopharma and medical devices | $215K | 193 mo ago | Funding Raised | — | 2003 | DebianYouTubeApache HTTP Server+10 | — | — |
Top 12 Biopharma Outsourcing companies in Cambridge
#1
Series A · Cambridge, Massachusetts · founded 2019 · 10 employees$11.8Mraised▾
Developer of therapeutic drugs
- Feb 2025Conventional Debt$6M
- Jul 2024Series A$1.8M
- Feb 2024Series A$4.1M
- Feb 2020Grant (prize money)—
#2
Seed · Cambridge, Massachusetts · founded 2021 · 9 employees$7.1Mraised▾
Developer of circular single-stranded DNA for targeted gene-length DNA correction. They focus on optimized DNA donor material using fermentation-based single-stranded DNA production. This enables gene-length circular single-stranded DNA templates for genomic engineering. The company's DNA donors complement CRISPR or other gene editing tools used to insert synthetic genes. They are building a databank linking single-stranded DNA sequence design to activity.
- May 2024Seed$5M
#3
Series A · Cambridge, Massachusetts · founded 2021 · 27 employees$100Mraised▾
Provider of small molecular medicine development and analytics services
- Oct 2022Series A$70M
- Nov 2021Seed$30M
#4
Funding Raised · Cambridge, Massachusetts · founded 2021 · 9 employees$844.4Kraised▾
Developer of biomaterial platform using synthetic biology for diverse chemistry applications. The technology couples genome and ribosome engineering to produce novel biologics. The platform unites the precision of biology with the diversity of chemistry to create template-directed biomaterials. The research and development platform enables the generation of an internal pipeline.
- Jun 2024Grant (prize money)$295.3K
- Mar 2024Grant (prize money)$274.7K
- Aug 2023Grant (prize money)$274.5K
#5
Series E · Cambridge, Massachusetts · founded 2001 · 12 employees$111.9Mraised▾
Hydra Biosciences develops drugs to treat pain, inflammation, cardiovascular and other diseases using its proprietary technology in novel ion channels. Its product pipeline includes HX-100 in phase 1 development stage for painful diabetic neuropathy and allergic asthma. Besides, it has pre-clinical drug candidates for dermatological disorders and pulmonary fibrosis. Additionally, it has partnered with Boehringer - Ingelheim for developing drugs for CNS disorders and renal disease.
- Mar 2015Series E$10.5M
- Jan 2009Series D$22M
- Mar 2008Series C$34M
- Nov 2007Series C$17M
#6
Seed · Cambridge, Massachusetts · founded 2017 · 60 employees$6Mraised▾
Provider of drug target discovery platform and probe library. The company offers its chemoproteomic platform, protein MS platforms, propriety probe library for identification, target selectivity and toxicity for drug discovery process.
- Dec 2022Seed$6M
#7
Series B · Cambridge, Massachusetts · founded 2017 · 15 employees$15Mraised▾
Developer of sustainable therapeutics and nutraceuticals using natural product manufacturing. The company focuses on genomics, metabolomics, and synthetic biology to manufacture natural products. It aims to improve human health and promote environmental sustainability through its scientific advancements. The company explores molecule-decoration to create more soluble and potent molecules.
- Nov 2020Series B$10M
- Apr 2019Series A$3M
- Aug 2018Seed$2M
#8
Series A · Cambridge, Massachusetts · founded 2010 · 3 employees$4.8Mraised▾
Provider of diabetes management and lifestyle modification services. It offers a range of services focused on diabetes care, including dietary guidance, exercise programs, and medical management. The services aim to help patients control their diabetes and improve their overall health and well-being through a holistic approach. A key component is a specialized diet kitchen providing guidance on appropriate food choices. Educational resources are also provided to empower patients in managing their condition.
- 2015Series A$3.2M
- Dec 2014Seed$1.6M
- Oct 2014Grant (prize money)$500K
#9
Acquired · Cambridge, Massachusetts · founded 1987 · 509 employees$2Mraised▾
Provider of data analysis and statistical solutions for the life sciences industry. It offers solutions for clinical trial design, analysis, and real world evidence, as well as data analytics and insights for the life sciences industry. It provides a range of software and services to support the drug development process. It includes solutions for clinical trial design, data analysis, and regulatory submissions.
- Nov 2017Series A—
- May 2015Grant (prize money)$99.6K
- Jun 2010Grant (prize money)$184.5K
- Jun 2010Grant (prize money)$1.1M
#10
Acquired · Cambridge, Massachusetts · founded 1999 · 30 employees$2.4Mraised▾
Global healthcare market research partner providing insights for biopharma and medtech. Specializing in primary market research methods, the company delivers insights to develop and commercialize healthcare products. Services include custom market research and recruitment for non-interventional clinical trials. They offer expertise in qualitative and quantitative research, advanced analytics, and strategic consulting. The company supports the commercialization of healthcare products through branding, concept testing, market assessments, and strategic forecasting. They build relationships with healthcare professionals and patients globally, facilitating market research studies. The company is passionate about providing research to move products to their next phase.
- Jan 2015Series D$155K
- Jan 2009Series D$750K
- Feb 2005Series C—
- Feb 2001Series B$1M
#11
Deadpooled · Cambridge, Massachusetts · founded 2007 · 3 employees$905.6Kraised▾
IOTA Pharma offers services to the pharmaceutical industry in the emerging area of fragment-based drug discovery. Activities completely span the hit finding and lead optimization stages of drug development, and include target analysis, focused fragment library construction, in silico screening, biochemical and biophysical screening, structure- and ligand-based design and medicinal chemistry services. IOTA offers the following screening services - Virtual screening packages, Surface Plasmon Resonance (SPR) screening package, High-sensitivity biochemical screening package, Nuclear Magnetic Resonance (NMR) screening package, Co-crystallography of Fragment-based leads. IOTA also offers a unique "Diverse 1500" fragment Library, in a number of formats, dispatched as pre-weighed, dry powders in individually sealed tubes. The company partners in two European projects in neglected parasitic diseases and glioblastoma (total value of €18.5m), which are developing specific approaches in Fragment-based Lead Discovery and Natural Product Screening to clinical disease. Human glioblastoma is a key therapeutic focus, in which the company coordinates a global glioblastoma research network.
- Jan 2017Grant (prize money)$402.7K
- Jan 2014Grant (prize money)$502.9K
#12
Acquired · Cambridge, Massachusetts · founded 2014 · 43 employees$224.6Kraised▾
CDMO providing API development, manufacturing, and analytical services. They offer custom API development, generic API manufacturing, and peptide development. Their expertise includes process development, analytical testing, solid-state chemistry, and formulation development. They provide solutions for early-phase to commercial drug development, including IND enabling services and technology transfer. They leverage continuous flow, biocatalysis, and complex synthetics. They design and build reactors. They offer analytical services like method development, stability testing, and microbiology. They focus on quality, regulatory compliance, and supply chain resilience. They provide GMP manufacturing for drug substances. They use advanced technologies and data-rich experimentation.
- Sep 2020Seed—
- Dec 2016Grant (prize money)$224.6K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Biopharma Outsourcing coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology in Cambridge is moving
A read on the academic research around Biotechnology in Cambridge — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 62 papers.
- University of Cambridge54
- Cambridge School4
- Cambridge University Hospitals NHS Foundation Trust4
- Cancer Research UK Cambridge Center3
- Cambridge Life Sciences1
- Chromatin1→3
- Antibody3
- Fermentation2
- Transcription (linguistics)2
- Gene2
- Methylation2
- Cell adhesion1
- Cell adhesion molecule1
- Follicular dendritic cells1
- Endocytosis1
- Neural cell adhesion molecule1
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.